KURA -
Kura Oncology, Inc.
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 11.0 0.26 (2.32%) |
0.0 (0.0%) |
0.01 (0.04%) |
0.03 (0.22%) |
0.01 (0.09%) |
0.39 (3.54%) |
-0.17 (-1.55%) |
0.03 (0.27%) |
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Earnings & Ratios
- Basic EPS:
- -0.75
- Diluted EPS:
- -0.75
- Basic P/E:
- -15.0067
- Diluted P/E:
- -15.0067
- RSI(14) 1m:
- 54.55
- VWAP:
- 11.26
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
Nov 25, 2025 22:16
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
Oct 18, 2025 07:23
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications
Oct 10, 2025 08:54
10 Health Care Stocks With Whale Alerts In Today's Session
Sep 29, 2025 17:35
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
Sep 25, 2025 21:18
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
Jun 02, 2025 22:00
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Jun 01, 2025 23:00
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
May 22, 2025 21:30
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Sep 30, 2024 22:30
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
Jun 24, 2024 11:30